{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-26-000053","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-06-25T21:00:32+00:00","discovered_at":"2026-06-25T21:02:00.245775+00:00","generated_at":"2026-06-25T21:02:54.361080+00:00","sec_items":["5.07"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Shareholders approve sale of Cumberland's FDA-approved products to Apotex","bullets":["Shareholders voted 10,492,455 For (99.84% of votes cast), 15,904 Against, 1,267 Abstain.","Transaction involves sale of FDA-approved commercial products and related assets to Apotex Inc.","Approval allows Cumberland to integrate products with Apotex's U.S. branded business per April 22, 2026 APA.","Special meeting held June 24, 2026; quorum of 70.14% of outstanding shares (10,509,626 shares represented)."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-26-000053","json":"https://secwatch.observer/filing/0001087294-26-000053.json","markdown":"https://secwatch.observer/filing/0001087294-26-000053.md","text":"https://secwatch.observer/filing/0001087294-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000053/0001087294-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000053/cpix-20260624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:02:54.361080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}